<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373281</url>
  </required_header>
  <id_info>
    <org_study_id>CYD14</org_study_id>
    <secondary_id>UTN: U1111-1116-4957</secondary_id>
    <nct_id>NCT01373281</nct_id>
  </id_info>
  <brief_title>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</brief_title>
  <official_title>Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to assess the efficacy of the CYD dengue vaccine in preventing
      symptomatic, virologically-confirmed dengue cases.

      Primary Objective:

      To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in
      preventing symptomatic virologically-confirmed dengue cases, regardless of the severity, due
      to any of the four serotypes in children aged 2 to 14 years at the time of inclusion.

      Secondary Objectives:

      To describe the efficacy of CYD dengue vaccine after each dose in:

        -  Preventing symptomatic virologically-confirmed dengue cases due to any of the four
           serotypes

        -  Preventing symptomatic dengue cases, either virologically-confirmed or probable based on
           serological criteria, due to any of the four serotypes

      To describe the occurrence of serious adverse events (SAEs), including serious adverse events
      of special interest in all subjects throughout the trial period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to either receive 3 injections of CYD dengue vaccine or a
      placebo at 0, 6, and 12 months.

      A subset of participants from each country will also be evaluated for reactogenicity and
      immunogenicity to enable the generation of country-specific data on reactogenicity,
      immunogenicity, and baseline dengue and JE antibody levels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</measure>
    <time_frame>28 days and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Person-years at Risk for Participants With Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</measure>
    <time_frame>28 days and up to 14 months post-injection 3</time_frame>
    <description>The person-years at risk was the cumulative time (in years) until the participant was diagnosed with VCD or until the end of the active period, whichever came first. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk. The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density Incidence of Symptomatic Virologically Confirmed Dengue Cases Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</measure>
    <time_frame>28 days and up to 14 months post-injection 3</time_frame>
    <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
Density incidence: data are cases per 100 person-years at risk. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With CYD Dengue Tetravalent Vaccine</measure>
    <time_frame>Pre-vaccination 1 and Day 28 post each vaccination up to 25 months (visit 07)</time_frame>
    <description>Geometric mean titers against each serotypes of the Dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of 2,000 subjects from each country (1,333 in the CYD Dengue Vaccine Group and 667 in the Control Group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Flavi Virus-Immuned Participants at Baseline With Antibody Titers ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine</measure>
    <time_frame>Pre-vaccination 1 and Day 28 post each vaccination up to 25 months (visit 07)</time_frame>
    <description>Neutralizing antibody levels against each of the 4 parental dengue virus strains of Sanofi Pasteur's CYD dengue vaccine constructs were measured using the dengue plaque reduction neutralization test (PRNT). Flavi virus (FV) immune participants at baseline are defined as those participants with ≥ 10 1/dil for at least one serotype with the parental dengue virus strain or for Yellow Fever titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited Injection-site and Systemic Reactions Following Any and Each Injection With CYD Dengue Tetravalent Vaccine</measure>
    <time_frame>Day 0 up to Day 14 post each vaccination</time_frame>
    <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited injection site reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm. Grade 3 Solicited injection site reactions: Fever, ≥39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10275</enrollment>
  <condition>Dengue</condition>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>Dengue Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CYD dengue vaccine at 0, 6, and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo vaccine at 0, 6, and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, dengue serotype 1, 2, 3, 4 virus</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Dengue Vaccine Group</arm_group_label>
    <other_name>CYD Dengue Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo: NaCl 0.9%</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2 to 14 years on the day of inclusion and resident of the site zone

          -  Subject in good health, based on medical history and physical examination

          -  Assent form or informed consent form has been signed and dated by the subject (based
             on local regulations), and informed consent form has been signed and dated by the
             parent(s) or another legally acceptable representative (and by an independent witness
             if required by local regulations)

          -  Subject able to attend all scheduled visits and to comply with all trial procedures.
             Exclusion Criteria:

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be pre-menarche for at least 1 year,
             surgically sterile, or using an effective method of contraception or abstinence from
             at least 4 weeks prior to the first vaccination until at least 4 weeks after the last
             vaccination).

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Self-reported or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection

          -  Self-reported systemic hypersensitivity to any of the vaccine components, or history
             of a life-threatening reaction to the vaccine used in the trial or to a vaccine
             containing any of the same substances

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination

          -  Deprived of freedom by administrative or court order, or in an emergency setting, or
             hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that might interfere with the ability to
             comply with trial procedures

          -  Identified as a site employee of the Investigator or study center, with direct
             involvement in the proposed study or other studies under the direction of that
             Investigator or study center, as well as a family member (i.e., immediate, husband,
             wife and their children, adopted or natural) of the site employees or the
             Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <zip>80114</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Pablo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muang District</city>
        <state>Kamphaeng Phet Province</state>
        <zip>6200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ban Pong Districts</city>
        <state>Ratchaburi Province</state>
        <zip>70110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Photharam Districts</city>
        <state>Ratchaburi Province</state>
        <zip>70120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Xuyen City</city>
        <state>An Giang Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>My Tho City</city>
        <state>Tien Giang Province</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <reference>
    <citation>L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL; CYD14 Primary Study Group; CYD15 Primary Study Group. Symptomatic Dengue in Children in 10 Asian and Latin American Countries. N Engl J Med. 2016 Mar 24;374(12):1155-66. doi: 10.1056/NEJMoa1503877.</citation>
    <PMID>27007959</PMID>
  </reference>
  <results_reference>
    <citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10.</citation>
    <PMID>25018116</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>September 15, 2015</results_first_submitted>
  <results_first_submitted_qc>October 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2015</results_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Dengue fever</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD dengue vaccine</keyword>
  <keyword>Flavivirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study subjects were enrolled from 03 June 2011 to 01 December 2011 at 9 sites in Indonesia, 5 in Malaysia, 3 in Thailand, 5 in Philippines, and 2 in Vietnam.</recruitment_details>
      <pre_assignment_details>A total of 10275 subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled; 3 subjects were not vaccinated and were excluded from the Full Analysis Set for Efficacy and the Safety Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6851"/>
                <participants group_id="P2" count="3424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6772"/>
                <participants group_id="P2" count="3379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6851"/>
            <count group_id="B2" value="3424"/>
            <count group_id="B3" value="10275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6851"/>
                    <measurement group_id="B2" value="3424"/>
                    <measurement group_id="B3" value="10275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="3.45"/>
                    <measurement group_id="B2" value="8.8" spread="3.42"/>
                    <measurement group_id="B3" value="8.8" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3524"/>
                    <measurement group_id="B2" value="1767"/>
                    <measurement group_id="B3" value="5291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3327"/>
                    <measurement group_id="B2" value="1657"/>
                    <measurement group_id="B3" value="4984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2335"/>
                    <measurement group_id="B2" value="1166"/>
                    <measurement group_id="B3" value="3501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="937"/>
                    <measurement group_id="B2" value="464"/>
                    <measurement group_id="B3" value="1401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1246"/>
                    <measurement group_id="B2" value="624"/>
                    <measurement group_id="B3" value="1870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="778"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="1170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1555"/>
                    <measurement group_id="B2" value="778"/>
                    <measurement group_id="B3" value="2333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
        <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
        <time_frame>28 days and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic virologically confirmed dengue cases were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
          <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
          <population>Number of symptomatic virologically confirmed dengue cases were assessed in the Per-Protocol Analysis Set.</population>
          <units>Cases per 100 person-years at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6710"/>
                <count group_id="O2" value="3350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% confidence interval (CI) of the vaccine efficacy. The CI was calculated using the exact method conditional on the total number of cases in both groups. The vaccine efficacy of the CYD dengue vaccine was considered significant if the lower bound of its 95% CI was greater than 25%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>56.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.8</ci_lower_limit>
            <ci_upper_limit>66.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With CYD Dengue Tetravalent Vaccine</title>
        <description>Geometric mean titers against each serotypes of the Dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of 2,000 subjects from each country (1,333 in the CYD Dengue Vaccine Group and 667 in the Control Group).</description>
        <time_frame>Pre-vaccination 1 and Day 28 post each vaccination up to 25 months (visit 07)</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in a subset of the Full Analysis Set for Immunogenicity (FASI), subjects who received at least one dose of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subset of subjects who received at least one dose of CYD Dengue vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subset of subjects who received at least one dose of the placebo vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Injection With CYD Dengue Tetravalent Vaccine</title>
          <description>Geometric mean titers against each serotypes of the Dengue virus strains were assessed using the plaque reduction neutralization test (PRNT) in a pre-defined subset of 2,000 subjects from each country (1,333 in the CYD Dengue Vaccine Group and 667 in the Control Group).</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in a subset of the Full Analysis Set for Immunogenicity (FASI), subjects who received at least one dose of vaccine.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1323"/>
                <count group_id="O2" value="660"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="33.8" upper_limit="43.5"/>
                    <measurement group_id="O2" value="42.1" lower_limit="35" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" lower_limit="137" upper_limit="170"/>
                    <measurement group_id="O2" value="46.1" lower_limit="38.2" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="150" upper_limit="183"/>
                    <measurement group_id="O2" value="46.6" lower_limit="38.7" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 1 Post Inj 3 (V 07)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="92.8" upper_limit="119"/>
                    <measurement group_id="O2" value="57.3" lower_limit="46.9" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="48.7" upper_limit="62.9"/>
                    <measurement group_id="O2" value="62.1" lower_limit="51.7" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="329" upper_limit="394"/>
                    <measurement group_id="O2" value="69.5" lower_limit="57.7" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355" lower_limit="327" upper_limit="386"/>
                    <measurement group_id="O2" value="68.5" lower_limit="57.1" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 1 Post-inj. 3 (V 07)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="175" upper_limit="241"/>
                    <measurement group_id="O2" value="78.4" lower_limit="65.1" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="35.6" upper_limit="45.1"/>
                    <measurement group_id="O2" value="40.7" lower_limit="34.5" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="184" upper_limit="223"/>
                    <measurement group_id="O2" value="40.8" lower_limit="34.6" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" lower_limit="189" upper_limit="226"/>
                    <measurement group_id="O2" value="42.5" lower_limit="36.2" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 1 Post Inj. 3 (V 07)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="168" upper_limit="206"/>
                    <measurement group_id="O2" value="62.4" lower_limit="51.9" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="22.9" upper_limit="28"/>
                    <measurement group_id="O2" value="26.2" lower_limit="22.6" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="139" upper_limit="163"/>
                    <measurement group_id="O2" value="24.4" lower_limit="21.3" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="141" upper_limit="162"/>
                    <measurement group_id="O2" value="26" lower_limit="22.6" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 1 Post Inj. 3 (V 07)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="78.5" upper_limit="93"/>
                    <measurement group_id="O2" value="26.2" lower_limit="22.5" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Flavi Virus-Immuned Participants at Baseline With Antibody Titers ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine</title>
        <description>Neutralizing antibody levels against each of the 4 parental dengue virus strains of Sanofi Pasteur's CYD dengue vaccine constructs were measured using the dengue plaque reduction neutralization test (PRNT). Flavi virus (FV) immune participants at baseline are defined as those participants with ≥ 10 1/dil for at least one serotype with the parental dengue virus strain or for Yellow Fever titer.</description>
        <time_frame>Pre-vaccination 1 and Day 28 post each vaccination up to 25 months (visit 07)</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in the Per-Protocol Analysis Set for Immunogenicity population, i.e. those who received vaccine 3 doses in the Immunogenicity subset only.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Flavi Virus-Immuned Participants at Baseline With Antibody Titers ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's CYD Dengue Vaccine</title>
          <description>Neutralizing antibody levels against each of the 4 parental dengue virus strains of Sanofi Pasteur's CYD dengue vaccine constructs were measured using the dengue plaque reduction neutralization test (PRNT). Flavi virus (FV) immune participants at baseline are defined as those participants with ≥ 10 1/dil for at least one serotype with the parental dengue virus strain or for Yellow Fever titer.</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in the Per-Protocol Analysis Set for Immunogenicity population, i.e. those who received vaccine 3 doses in the Immunogenicity subset only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1303"/>
                <count group_id="O2" value="652"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1"/>
                    <measurement group_id="O2" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post-injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post-injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                    <measurement group_id="O2" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre-injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited Injection-site and Systemic Reactions Following Any and Each Injection With CYD Dengue Tetravalent Vaccine</title>
        <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited injection site reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm. Grade 3 Solicited injection site reactions: Fever, ≥39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
        <time_frame>Day 0 up to Day 14 post each vaccination</time_frame>
        <population>Solicited injection site reactions and systemic reactions were assessed in a subset of the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited Injection-site and Systemic Reactions Following Any and Each Injection With CYD Dengue Tetravalent Vaccine</title>
          <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited injection site reactions (2-11 years): Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited injection site reactions (12-14 years): Pain, Significant, prevents daily activity; Erythema and Swelling, &gt;100 mm. Grade 3 Solicited injection site reactions: Fever, ≥39°C; Headache, Malaise, Myalgia, and Asthenia, Significant, prevents daily activity.</description>
          <population>Solicited injection site reactions and systemic reactions were assessed in a subset of the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1334"/>
                <count group_id="O2" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                    <measurement group_id="O2" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Inj site Pain (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Inj. site Erythema (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Inj. site Swelling (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post any injection)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Person-years at Risk for Participants With Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
        <description>The person-years at risk was the cumulative time (in years) until the participant was diagnosed with VCD or until the end of the active period, whichever came first. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk. The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
        <time_frame>28 days and up to 14 months post-injection 3</time_frame>
        <population>Vaccine Efficacy Against Symptomatic Virologically confirmed Dengue Cases were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Person-years at Risk for Participants With Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
          <description>The person-years at risk was the cumulative time (in years) until the participant was diagnosed with VCD or until the end of the active period, whichever came first. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk. The vaccine efficacy is considered as significant if the lower bound of its 95% CI (exact method by Breslow &amp; Day) is greater than 25%.</description>
          <population>Vaccine Efficacy Against Symptomatic Virologically confirmed Dengue Cases were assessed in the Per-Protocol Analysis Set.</population>
          <units>Cumulative time (in years) until VCD</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6710"/>
                <count group_id="O2" value="3350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6526"/>
                    <measurement group_id="O2" value="3227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density Incidence of Symptomatic Virologically Confirmed Dengue Cases Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
        <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
Density incidence: data are cases per 100 person-years at risk. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk.</description>
        <time_frame>28 days and up to 14 months post-injection 3</time_frame>
        <population>Density incidence of symptomatic virologically confirmed dengue cases were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subjects received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of placebo vaccine, one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Density Incidence of Symptomatic Virologically Confirmed Dengue Cases Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine</title>
          <description>Symptomatic virologically-confirmed dengue (VCD) cases were defined as acute febrile illness (temperature ≥38°C on at least 2 consecutive days) and confirmed by dengue reverse transcriptase polymerase chain reaction and/or dengue NS1 enzyme-linked immunosorbent assay. Cases defined as number of subjects with at least one symptomatic VCD episode from 28 days post-injection 3 to the end of Active Phase.
Density incidence: data are cases per 100 person-years at risk. Data presented is the sum of individual units of time for which the participants contributed to the analyses. Incidence density was calculated as the number of VCD cases divided by the cumulative person-years at risk.</description>
          <population>Density incidence of symptomatic virologically confirmed dengue cases were assessed in the Per-Protocol Analysis Set.</population>
          <units>Cases per 100 person-year at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6710"/>
                <count group_id="O2" value="3350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to 13 months post 3rd vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Safety data were collected in subjects that received at least 1 dose of CYD dengue vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Safety data were collected in subjects that received at least 1 dose of placebo vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="355" subjects_at_risk="6848"/>
                <counts group_id="E2" subjects_affected="220" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Rheumatic heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Choroidal dystrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Salivary gland mucocoele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Abscess of external auditory meatus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6848"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Brucellosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="6848"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="6848"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lymphadenitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6848"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6848"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6848"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>ear injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Genital injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="6848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Tracheal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Contussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lip neoplasm benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6848"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Post streptococcal glomerulonephritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="6848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
              <event>
                <sub_title>Victim of sexual abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="614" subjects_at_risk="6848"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="3424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site Pain</sub_title>
                <counts group_id="E1" events="992" subjects_affected="614" subjects_at_risk="1332"/>
                <counts group_id="E2" events="449" subjects_affected="275" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Injection-site Erythema</sub_title>
                <counts group_id="E1" events="142" subjects_affected="107" subjects_at_risk="1332"/>
                <counts group_id="E2" events="71" subjects_affected="52" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Injection-site Swelling</sub_title>
                <counts group_id="E1" events="84" subjects_affected="68" subjects_at_risk="1332"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="269" subjects_affected="248" subjects_at_risk="1332"/>
                <counts group_id="E2" events="128" subjects_affected="118" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="687" subjects_affected="476" subjects_at_risk="1332"/>
                <counts group_id="E2" events="352" subjects_affected="239" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="529" subjects_affected="378" subjects_at_risk="1332"/>
                <counts group_id="E2" events="244" subjects_affected="167" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="113" subjects_affected="85" subjects_at_risk="1334"/>
                <counts group_id="E2" events="61" subjects_affected="45" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="104" subjects_affected="95" subjects_at_risk="1334"/>
                <counts group_id="E2" events="62" subjects_affected="54" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="585" subjects_affected="414" subjects_at_risk="1332"/>
                <counts group_id="E2" events="292" subjects_affected="197" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="853" subjects_affected="562" subjects_at_risk="1332"/>
                <counts group_id="E2" events="399" subjects_affected="259" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="69" subjects_affected="63" subjects_at_risk="1334"/>
                <counts group_id="E2" events="61" subjects_affected="48" subjects_at_risk="663"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="1334"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="663"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

